Key Highlights

  • Surgery Partners (NASDAQ:SGRY) traded at USD 23.36 on October 28, 2026, up 64.70% over one month, up 53.75% over one week, up 41.80% over three months and up 51.26% year to date, per published market data.
  • HealthSpan Partners, an affiliate of Bon Secours Mercy Health, agreed on October 26, 2026 to buy Surgery Partners (NASDAQ:SGRY) for USD 23.50 per share in cash, a deal worth about USD 5.7 billion.
  • The shares closed at USD 23.25 on October 26 after a 47.62% jump, which implies a prior close near USD 15.75, so the offer was about 49% above that level, simple arithmetic on published numbers.
  • Closing is expected in the first quarter of 2027, subject to regulatory approvals, and Bain Capital, which holds roughly 39%, is reported to support the transaction, which lowers one approval hurdle.

The Deal and Its Price

On October 26, 2026, HealthSpan Partners, an affiliate of Bon Secours Mercy Health, announced an agreement to acquire Surgery Partners (NASDAQ:SGRY) for USD 23.50 per share in cash, a transaction worth about USD 5.7 billion. Earlier published reports had pointed to a price near USD 20 per share, so the final price came in above those talks. The shares ended October 26 at USD 23.25, up 47.62%, and now sit at USD 23.36, about 0.6% below the offer. A gap that narrow suggests investors expect completion in the first quarter of 2027, with regulatory approvals still to come. Surgery centers perform planned procedures outside traditional hospitals, which can lower costs for payers and patients.

Debt and Bain's Role

Surgery Partners operates about 176 surgery centers and hospitals across 30 states, according to published reports. Debt rose from USD 2.97 billion in fiscal 2022 to USD 4.04 billion in fiscal 2025, which is why the equity value is a small part of the enterprise price. Bain Capital has been a shareholder since 2017 and holds roughly 39%, and it had tried to buy the whole company last year at an enterprise value of USD 6.7 billion before walking away. The 41.80% three-month gain and 51.26% year to date gain show how much of the rally came from this deal. Those figures are from published reports and should be checked against the company's annual filing.

Risks and What to Watch

Regulatory review is the main risk, because a hospital system buying a large surgery network can draw scrutiny, and a delay would keep the shares tied to the spread. A failed deal could send the stock back toward its pre-announcement level near USD 15.75, simple arithmetic. With a one-week gain of 53.75% already banked, new upside is capped by the USD 23.50 price. Watch the proxy statement, the shareholder vote and any antitrust requests for information. This is not advice. The mechanism is a merger spread: arbitrage buyers purchase below the offer and earn the difference only if the deal closes, so a small gap means a high perceived chance.

Where Things Stand

The answer is that an all-cash buyout explains the month. HealthSpan Partners agreed on October 26, 2026 to pay USD 23.50 per share for Surgery Partners (NASDAQ:SGRY), and the shares now trade about 0.6% below that price. The prior close near USD 15.75 is the reference for the premium of about 49%. Completion depends on regulatory approvals in a process expected to finish in the first quarter of 2027, so the next catalysts are the proxy and any antitrust review.